Corpus overview


Overview

MeSH Disease

Human Phenotype

Vomiting (17)

Diarrhea (16)

Cough (15)

Fever (14)

Nausea and vomiting (7)


Transmission

Seroprevalence
    displaying 1 - 10 records in total 24
    records per page




    Gastrointestinal symptoms in coronavirus disease MESHD 2019: a cross-sectional study in Wuhan, China

    Authors: Yong Zhang; Zuneng Lu; Bo Wang; Jinxing Chang; Yonggang Ma

    doi:10.21203/rs.3.rs-69884/v1 Date: 2020-09-01 Source: ResearchSquare

    Background To investigate the clinical symptoms of coronavirus disease MESHD 2019 (COVID-19), particularly the prevalence SERO, time of symptom onset TRANS, and duration of gastrointestinal ( GI MESHD) symptoms.Methods This was a cross-sectional study using paper questionnaires. COVID-19 patients in a temporary hospital in Wuhan voluntarily completed surveys collecting data on COVID-19 symptoms and investigation results.Results A total of 212 adults TRANS were enrolled in this study, of whom 127 (59.9%) were female TRANS, mean age TRANS was 48.50 ± 13.15 years. Concerning symptoms, 78.8% (167/212) had fever HP fever MESHD, and 66% (140/212) had cough HP. Diarrhoea MESHD occurred in 43.8% (93/212) of patients. Nausea and vomiting HP Nausea and vomiting MESHD vomiting MESHD were also common (20.7%). Fever HP Fever MESHD and cough HP cough MESHD were frequently the initial symptoms of COVID-19, and they lasted for 5.00 [interquartile range (IQR): 3.00–10.00] days and 10.00 (IQR: 5.00–24.00) days, respectively. Most patients developed nausea and vomiting HP nausea and vomiting MESHD vomiting MESHD 2.00 (IQR: 0–9.00) days and diarrhoea MESHD 5.00 (IQR: 0.25–11.00) days after the onset of initial symptoms, respectively. There was a median duration of 4.00 (IQR: 2.00–8.75) days with diarrhoea MESHD, and 6.00 (IQR: 4.00–10.00) days with nausea and vomiting HP nausea and vomiting MESHD vomiting MESHD. The patients with diarrhoea MESHD were younger [45.85 ± 13.28 years vs 50.61 ± 12.82 years, P = 0.009] and were more likely to have an abnormal chest CT (95.7% vs 82.4%, P = 0.001) than those without diarrhoea MESHD.Conclusions In our cohort of patients, GI symptoms MESHD were common in COVID-19, occurred mostly during the middle stage of the disease, and lasted for a short duration. GI MESHD symptoms may not be associated with COVID-19 related treatment.

    COVID-19 Vaccine Candidates by Identification of B and T Cell Multi-Epitopes Against SARS-COV-2 MESHD

    Authors: Suresh Kumar; Sarmilah Mathavan; Wee Jia Jin; Nur Azznira Bt Azman; Devindren Subramanaiam; Nur Afiqah Binti Zainalabidin; Dhivashini Lingadaran; Zainah Binti Abdul Sattar; Danniya Lakshmi Manickam; Priscilla Sheba Anbananthan; Johan Ahmad Taqiyuddin; Yuvapriya Thevarajan

    id:10.20944/preprints202008.0092.v1 Date: 2020-08-04 Source: Preprints.org

    Coronavirus disease (COVID-19) is a new discovered strain where WHO officially declares the disease as COVID-19 while the virus responsible for it called Severe Acute Respiratory Syndrome Coronavirus 2 MESHD or SARS-CoV-2. The incubation period TRANS of this disease is between 14 days. Ordinary clinical symptoms that reported around the world include fever HP fever MESHD, cough HP cough MESHD, fatigue HP fatigue MESHD, diarrhoea MESHD and vomiting HP vomiting MESHD as well as asymptomatic TRANS for certain people. Infection is spread mainly through broad droplets. In early March 2020, WHO again has announced that COVID-19 is a pandemic with currently no specific treatment. The potential use of SARS-COV-2 proteome as a vaccine candidate by analysing through B-cell and T-cell antigenicity by using a immunoinformatics approach as a vaccine development early stage. In this study, we used consensus sequence for SARS-COV-2 proteome that was retrieved from NCBI database. VaxiJen 2.0 was mainly used to identify the antigenic property of SARS-COV-2 proteins. IEDB then used to analyse the B-cell epitope, the presence of T cell immunogenic epitope in SARS-COV-2 proteins was obtained by using compromise method of MHC class I and II tools that accessible respectively using ProPred-1 server and MHC II Binding Prediction in IEDB database. The best epitopes of B and T-cell epitopes were predicted with high antigencity and the information is disseminated through web-based database resource (https://covid-19.omicstutorials.com/epitopes/). This study will be useful to find a new epitope-based candidate for SARS-COV-2. However, further study needs to be done for the next stages of vaccine development.

    Clinical characteristics of neonates with coronavirus disease MESHD 2019 (COVID-19): a systematic review

    Authors: Yuan Hu; Jing Xiong; Yuan Shi

    doi:10.21203/rs.3.rs-50795/v1 Date: 2020-07-29 Source: ResearchSquare

    This study aimed to summarize the existing literature on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection MESHD in newborns to clarify the clinical features and outcomes of neonates with COVID-19. A systematic search was performed in PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang Data, and VIP databases from January 1, 2019 to April 30, 2020. The references of relevant studies were also searched. A descriptive summary was organized by aspects of clinical presentations (symptoms, laboratory examinations, and imaging) and outcomes. We identified 14 studies reporting 18 newborns with COVID-19. The most common clinical manifestations were fever HP fever MESHD (62.5%), shortness of breath MESHD (50.0%), diarrhea HP diarrhea MESHD/ vomiting HP vomiting MESHD/feeding intolerance(43.8%), cough HP (37.5%), dyspnea HP dyspnea MESHD (25.0%), and nasal congestion/runny nose/ sneeze HP(25.0%). Atypical symptoms included jaundice HP jaundice MESHD and convulsion MESHD. Lymphocyte numbers decreased in 5 cases, and radiographic findings were likely to show pneumonia HP pneumonia MESHD. All newborns recovered and discharged from the hospital, and there was no death.Conclusion: Clinical symptoms of neonatal SARS-CoV-2 infection MESHD are atypical, most of them are mild. Up to now, the prognosis of newborns is good, and there is no death. Intrauterine vertical transmission TRANS is possible, but confirmed evidence is still lacking. The Long-term follow-up of potential influences of SARS-CoV-2 infection MESHD on neonates need further exploration.

    A severe coronavirus disease MESHD 2019 patient with high-risk predisposing factors died from massive gastrointestinal bleeding MESHD: a case report

    Authors: Taojiang Chen; Qin Yang; Hongyu Duan

    doi:10.21203/rs.3.rs-45116/v1 Date: 2020-07-17 Source: ResearchSquare

    Background: SARS-CoV-2 is highly infectious and has been a significant public health threat. Despite typical manifestations of illness are dominated by respiratory symptom, some patients have concurrent gastrointestinal manifestations, including   nausea MESHD, diarrhea HP diarrhea MESHD, and vomiting HP vomiting MESHD. Massive gastrointestinal bleeding MESHD, however, has rarely been reported. Case presentation: We herein describe a case of severe SARS-CoV-2 infected MESHD patient with several risk factors for poor prognosis, including male TRANS, hypertension HP hypertension MESHD, old age TRANS, mixed bacterial infection MESHD and multilobular infiltration on radiological imaging. After improvement of respiratory status, the onset of gastrointestinal bleeding MESHD occurred, probably resulting from direct viral invasion as evidenced by the positive findings for SARS-CoV-2 in the repeat stool specimens. Although aggressive resuscitation was administered, hematochezia HP hematochezia MESHD was uncontrolled. The patient rapidly deteriorated, suffered cardiac arrest HP cardiac arrest MESHD, and expired. Conclusions: Digestive symptoms could be severe in SARS-CoV-2 infected MESHD patients, especially for the high-risk individuals with predisposing conditions. A more thorough protocol for preventing cross-infection MESHD through faecal-oral transmission TRANS should be implemented in the process of patient care and infection MESHD control.

    Comparison of Clinical Features on Admission Between Coronavirus Disease MESHD 2019 and Influenza A among Children TRANS: A Retrospective Study in China

    Authors: Feng Liang; Xianfeng Wang; Hui Li; Jun Chen; Lei Liu; Jianbo Shao; Yi Xu; Liya He; Huiying Liang; Kuanrong Li; Sitang Gong; Huimin Xia

    doi:10.21203/rs.3.rs-44748/v1 Date: 2020-07-17 Source: ResearchSquare

    Background: Coronavirus disease 2019 (COVID-19) share similar symptoms with influenza A (IA), but it is more worthwhile to understand the disparities of the two infections regarding their clinical characteristics on admission. Methods: A total of 71 age TRANS-matched pediatric IA and COVID-19 patient pairs were formed and their clinical data on admission were compared. Results: Fever HP Fever MESHD, cough HP cough MESHD, nasal congestion and nausea/vomiting HP nausea/vomiting MESHD vomiting MESHD were the most common symptoms on admission for both infections MESHD but occurred less often in COVID-19. The IA patients were more likely to have lower-than-normal levels of lymphocyte count and percentage and to have higher-than-normal levels of activated partial thromboplastin time, prothrombin time, serum SERO C-reactive protein, and serum SERO procalcitonin, while the COVID-19 patients had higher odds of having lower-than-normal levels of neutrophil count and percentage.Conclusions: This study suggests that influenza A is more symptomatic than COVID-19 for children TRANS and might be an overall more severe infection HP at the time of admission. 

    Acute acalculous cholecystitis MESHD cholecystitis HP on a COVID-19 patient: a case report

    Authors: Edoardo Mattone; Maria Sofia; Elena Schembari; Valentina Palumbo; Rosario Bonaccorso; Valentina Randazzo; Gaetano La Greca; Carmelo Iacobello; Domenico Russello; Saverio Latteri

    doi:10.21203/rs.3.rs-42230/v1 Date: 2020-07-13 Source: ResearchSquare

    Background coronavirus disease-19 (COVID-19) has spread to several countries around the world and has become an unprecedented pandemic. We report an extremely rare case of acute acalculous cholecystitis MESHD cholecystitis HP on a COVID-19 patient. In our knowledge, this is the first report of laparoscopic cholecystectomy performed on a COVID-19 patient.Case presentation: a COVID-19 patient was diagnosed with acute acalculous cholecystitis MESHD cholecystitis HP and a multidisciplinary team decided to perform a percutaneous transhepatic biliary drainage (PTBD) as the first treatment. SARS-CoV-2 RNA was not found in the bile fluid. Because of deterioration of the patient’s clinical conditions, laparoscopic cholecystectomy had to be performed and since the gallbladder was gangrenous MESHD, the severe inflammation MESHD made surgery difficult to perform.Conclusions acalculous cholecystitis MESHD cholecystitis HP was related with mechanical ventilation and prolonged total parenteral nutrition, in this case the gangrenous MESHD histopathology pattern and the gallbladder wall ischemia MESHD was probably caused by vascular insufficiency MESHD secondary to severe acute respiratory distress syndrome MESHD respiratory distress HP syndrome of COVID-19 pneumonia MESHD pneumonia HP. The percutaneous transhepatic gallbladder drainage (PTBD) was performed according to Tokyo Guidelines because of high surgical risk. Laparoscopic cholecystectomy was next performed due to no clinical improvement. The absence of viral RNA in the bile highlights that SARS-CoV-2 is not eliminated with the bile while it probably infects MESHD small intestinal enterocytes which is responsible of gastrointestinal symptoms such as anorexia HP anorexia MESHD, nausea, vomiting HP nausea, vomiting MESHD vomiting MESHD, and diarrhea HP diarrhea MESHD. Although the lack of evidence and guidelines about the management of patient with acute cholecystitis MESHD cholecystitis HP during COVID-19 pandemic, laparoscopic cholecystectomy, at most preceded by PTGBD on high surgical risk patients, remains the gold standard for the treatment of acute cholecystitis MESHD cholecystitis HP on COVID-19 patients.

    Symptomatology of Coronavirus Disease MESHD 2019 (COVID-19) - Lessons from A Meta-Analysis Across 13 Countries

    Authors: Champika Saman Kumara Gamakaranage; Dineshani Hettiarachchi; Dileepa Ediriweera; Saroj Jayasinghe

    doi:10.21203/rs.3.rs-39412/v1 Date: 2020-07-01 Source: ResearchSquare

    Background: COVID-19 pandemic has resulted in varying clinical manifestations and mortality rates. There is no consensus on the symptomatology that would guide researchers and clinicians.Objective: The objective of the study was to identify symptoms and their frequencies of coronavirus disease MESHD 2019 with a meta-analysis of studies from several countries. Data sources: A systematic review using PubMed and Google Scholar data sources and reference tracing TRANS were used to identify 7176 relevant articles. Eligibility criteria: Suitable articles were selected manually with selection criteria and 14 original articles included for meta-analysis. Data abstraction analysis: PRISMA guideline was used for abstracting data. Then a table was generated by feeding it with numbers and proportions of each symptom described in original studies. A meta-analysis was carried out using random effect models on each symptom separately across the studies and their prevalence SERO rates and 95% confident intervals calculated.Results: We identified 14 relevant scientific papers, either cross-sectional or cohort studies and analyzed. There were 2,660 cases of COVID-19. he majority were from China (n=2,439, 91.7%) and remainder from the Netherlands, Italy, Korea and India and one article from Europe. There was a total of 32 symptoms (i.e. present in >50% of patients):  fever MESHD (79.56%, 95% CI: 72.17-86.09%), malaise (63.3%, 95% CI: 53.1 – 73.0%), cough HP (56.7. %, 95% CI: 48.6 - 64.6 %) and cold (55.6%, 95% CI: 45.2 – 65.7%). Symptoms of intermediate incidence (5-49%) were; anosmia HP anosmia MESHD, sneezing HP, ocular pain HP ocular pain MESHD, fatigue HP fatigue MESHD, sputum production, arthralgia HP arthralgia MESHD, tachypnea HP tachypnea MESHD, palpitation HP, headache HP headache MESHD, chest tightness HP chest tightness MESHD, shortness of breath MESHD, chills HP, myalgia HP myalgia MESHD, sore throat, anorexia HP anorexia MESHD, weakness MESHD, diarrhea HP diarrhea MESHD, rhinorrhea HP rhinorrhea MESHD, dizziness MESHD, nausea HP nausea MESHD, altered level of consciousness, vomiting HP vomiting MESHD and abdominal pain HP abdominal pain MESHD. Rare symptoms (<5% of patients) were: tonsil swelling, haemoptysis, conjunctival injection, lymphadenopathy HP lymphadenopathy MESHD and rash MESHD were uncommon symptoms of coronavirus disease MESHD (<5%).Conclusion and implications of key findings: We found (25/32) symptoms to be present in =>5% of cases which could be considered as “typical” symptoms of COVID-19. The list of symptoms we identified are different from those documents released by the WHO, CDC, NHS, Chinese CDC, Institute Pasteur and Mayo Clinic. The compiled list would be useful for future researchers to document a comprehensive picture of the illness.

    Symptomatology of Coronavirus Disease MESHD 2019 (COVID-19) - Lessons from a meta-analysis across 13 countries

    Authors: Champika Saman Kumara Gamakaranage; Dineshani Hettiarachchi; Dileepa Ediriweera; Saroj Jayasinghe

    doi:10.21203/rs.3.rs-39412/v2 Date: 2020-07-01 Source: ResearchSquare

    Background: COVID-19 pandemic has resulted in varying clinical manifestations and mortality rates. There is no consensus on the symptomatology that would guide researchers and clinicians. Objective: The objective was to identify symptoms and their frequencies of COVID-19 with a meta-analysis of studies from several countries. Data sources: A systematic review using PubMed and Google Scholar data sources and reference tracing TRANS were used to identify 7176 articles. Eligibility criteria: Suitable articles were selected manually with selection criteria and 14 original articles included in meta-analysis. Data abstraction and analysis: PRISMA guidelines, used for data abstraction and a table was generated by feeding it with numbers and proportions of each symptom described. A meta-analysis was carried out using random effect models on each symptom separately across the studies and their prevalence SERO rates and 95% confident intervals were calculated.Results: Selected 14 studies, either cross-sectional or cohort studies are analyzed. There were 2,660 confirmed cases TRANS of COVID-19. The majority were from China (n=2,439, 91.7%) and remainder from the Netherlands, Italy, Korea and India and one article from Europe. There was a total of 32 symptoms identified from the meta-analysis and additional 7 symptoms were identified from reference searching. The most common symptoms were ( prevalence SERO >50%): fever HP fever MESHD (79.56%, 95% CI: 72.17-86.09%), malaise (63.3%, 95% CI: 53.1 – 73.0%), cough HP (56.7. %, 95% CI: 48.6 - 64.6 %) and cold (55.6%, 95% CI: 45.2 – 65.7%). Symptoms of intermediate incidence (5-49%) were; anosmia HP anosmia MESHD, sneezing HP, ocular pain HP ocular pain MESHD, fatigue HP fatigue MESHD, sputum production, arthralgia HP arthralgia MESHD, tachypnea HP tachypnea MESHD, palpitation HP, headache HP headache MESHD, chest tightness HP chest tightness MESHD, shortness of breath MESHD, chills HP, myalgia HP myalgia MESHD, sore throat, anorexia HP anorexia MESHD, weakness MESHD, diarrhea HP diarrhea MESHD, rhinorrhea HP rhinorrhea MESHD, dizziness MESHD, nausea HP nausea MESHD, altered level of consciousness, vomiting HP vomiting MESHD and abdominal pain HP abdominal pain MESHD. Rare symptoms (<5%): tonsil swelling MESHD, haemoptysis, conjunctival injection, lymphadenopathy HP lymphadenopathy MESHD and rash MESHD. Conclusion and implications of key findings: We found (25/32, from meta-analysis) symptoms to be present in =>5% of cases which could be considered as “typical” symptoms of COVID-19. The list of symptoms we identified is different from those documents released by the WHO, CDC, NHS, Chinese CDC, Institute Pasteur and Mayo Clinic. The compiled list would be useful for future researchers to document a comprehensive picture of the illness.  

    Differentiating coronavirus disease MESHD 2019 (COVID-19) from influenza and dengue

    Authors: Tun-Linn Thein; Li Wei Ang; Barnaby Edward Young; Mark IC Chen; Yee-Sin Leo; David Chien Lye

    doi:10.21203/rs.3.rs-36343/v1 Date: 2020-06-18 Source: ResearchSquare

    Background: The novel coronavirus disease MESHD 2019 (COVID-19) presents with non-specific clinical features. This may result in misdiagnosis or delayed diagnosis, and lead to further transmission TRANS in the community. We aimed to derive early predictors to differentiate COVID-19 from influenza and dengue.Methods: The study comprised 126 patients with COVID-19, 171 with influenza and 180 with dengue, who presented within 5 days of symptom onset TRANS. All cases were confirmed TRANS by reverse transcriptase polymerase chain reaction tests. We used logistic regression models to identify clinical characteristics and laboratory markers in classifying COVID-19 versus influenza, and COVID-19 versus dengue. The performance SERO of the models were evaluated using receiver operating characteristic curves (ROC).Results: Shortness of breath MESHD was the strongest predictor in the models for differentiating between COVID-19 and influenza, followed by diarrhoea MESHD. Higher lymphocyte count was predictive of COVID-19 versus influenza and versus dengue. In the model for differentiating between COVID-19 and dengue, patients with cough HP cough MESHD and higher platelet count were at increased odds of COVID-19, while headache HP headache MESHD, joint pain MESHD pain HP, skin rash HP skin rash MESHD and vomiting/nausea HP vomiting/nausea MESHD nausea MESHD were indicative of dengue. The area under the ROC was 0.92 for flu model and 0.99 for dengue model.Conclusion: Models based on clinical features and simple laboratory markers for differentiating COVID-19 from influenza and dengue, which possess good predictive performance SERO, can serve as a useful tool for primary care physicians to determine if further investigations or referrals would be required.

    Gastrointestinal symptoms and fecal nucleic acid testing of children TRANS with coronavirus disease MESHD 2019: a systematic review and meta-analysis

    Authors: Ji-Gan Wang; Hairong Cui; Huabo Tang

    doi:10.21203/rs.3.rs-34733/v1 Date: 2020-06-12 Source: ResearchSquare

    Objective: To understand the clinical manifestations and incidence of gastrointestinal symptoms of Coronavirus disease MESHD (COVID-19) in children TRANS and discuss the importance of fecal nucleic acid testing.Methods: Retrospective analysis of studies of gastrointestinal symptoms MESHD and fecal nucleic acid detection in pediatric COVID-19 since the outbreak of COVID-19, as well as prospective clinical studies and case reports to understand the clinical characteristics of gastrointestinal symptoms and feces in children TRANS. Nucleic acid detection results were also analyzed.Results: 1. The clinical manifestations of gastrointestinal symptoms in children TRANS with COVID-19 are mostly vomiting HP vomiting MESHD and diarrhea HP diarrhea MESHD, with a total incidence rate of 21.1% (95%Cl=0.14-0.28).2.When analyzing by country (studies from China versus studies from other countries), the pooled prevalence SERO of gastrointestinal symptoms in studies from countries other than China was much lower at 18.2% (95% CI0.05 to 0.31). This is in comparison to studies from China where the prevalence SERO was higher: 23.3% (95% CI 0.153 to 0.310) .3.In Wuhan patients, the pooled prevalence SERO was much higher at 41.2% (95 % CI 0.147 to 0.678) as compared to areas outside Wuhan,China:15.1%(95 % CI 0.075 to 0.227).4.Fecal nucleic acid detection is as accurate as respiratory specimen nucleic acid detection. The positive rate of fecal nucleic acid testing in COVID-19 patients was 92.5% (25/27). In patients where nucleic acid tests of respiratory tract specimens produced negative results, a positive fecal nucleic acid test result was present in 83.3% (20/24); one week after the respiratory tract specimen was nucleic acid-negative, 54.1% (13/24) were fecal nucleic acid-positive; two weeks after the respiratory tract nucleic acid negative test, 37.5% (9/24) were fecal nucleic acid-positive. The longest interval between a negative respiratory system result and positive fecal specimen result exceeded 19 days.Conclusions and Relevance: Gastrointestinal symptoms in pediatric COVID-19 are relatively common. Attention should be paid to the detection of fecal nucleic acids in children TRANS. Fecal nucleic acid-negative status should be considered as one of the desegregation standards.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.